Selecting antiretroviral therapies for human immunodeficiency virus type 1 -infected persons is complicated by the availability of a vast number of potentially useful drug combinations and by extensive variation among patients in their resistance to various drugs. AIDS clinical trials have used designs in which a handful of drug regimens in a few patient classes can be compared. Here is proposed implementation of innovative designs with factorial structure that permit assessment of many treatment arms and patient classes in a single trial; when and how they can be appropriately used are discussed. These designs are efficient, permit systematic investigation of correlations between genetic mutations and in vivo drug resistance, and provide insight into important drug interactions in people that conventional designs are unable to provide. Through creative application of these designs, identification of superior drug combinations and the science of understanding in vivo joint drug dynamics and genotypic resistance will progress at an optimum pace.
Selecting antiretroviral therapies for human immunodeficiency virus type 1 -infected persons is complicated by the availability of a vast number of potentially useful drug combinations and by extensive variation among patients in their resistance to various drugs. AIDS clinical trials have used designs in which a handful of drug regimens in a few patient classes can be compared. Here is proposed implementation of innovative designs with factorial structure that permit assessment of many treatment arms and patient classes in a single trial; when and how they can be appropriately used are discussed. These designs are efficient, permit systematic investigation of correlations between genetic mutations and in vivo drug resistance, and provide insight into important drug interactions in people that conventional designs are unable to provide. Through creative application of these designs, identification of superior drug combinations and the science of understanding in vivo joint drug dynamics and genotypic resistance will progress at an optimum pace.
The development of powerful antiretroviral therapies has of combination antiretroviral trials provides many opportunities for application of these efficient designs. dramatically changed the expectations and capabilities of the treatment of human immunodeficiency virus type 1 (HIV-1)
When only a handful of combination HIV-1 therapies was available for efficacy testing, it was rarely appropriate to con-infection -it may be possible to suppress virus permanently in some individuals [1 -4] . Because numerous antiretroviral duct a factorial trial. This is because at least 4 treatment arms must be arranged in a particular configuration, and for most drugs in multiple drug classes are under development or have recently been approved, there are hundreds of potential drug sets of arms that fit this structure, at least 1 was known a priori to be inferior to the others. For a typical example, in 1996 combinations that may be effective. In addition, there are a large number of important classifications of patients with regard Hoffmann-La Roche completed a 3-arm trial of saquinavir monotherapy versus dideoxycytosine (ddC) monotherapy versus to treatment history and degree of resistance to various antiretroviral drugs. Due to limited resources, only a fraction of possi-saquinavir/ddC combination. A 2 1 2 factorial design would require a placebo arm. Today, with the advent of hundreds of ble drug combinations in a fraction of patient classes can be investigated in conventionally designed efficacy trials, even if possible drug combinations, there are many factorial configurations for which equipoise holds. the primary end point is a surrogate marker, such as virologic response. This motivates consideration of innovative trial de-Interactions of antiretroviral drugs are commonly studied in the laboratory but not in the clinic, as nonfactorial trials do not signs that facilitate efficacy assessment of many drug combinations in many patient classes. In this paper, we argue the aptness have the capability of assessing in vivo interactions. Due to special considerations of HIV-1 disease and its management, of factorial and related structured designs.
Factorial designs have been used extensively in agricultural knowledge of interactions in people might help in developing combination therapies that meet their high promise of capably and industrial experiments, and to a lesser degree in clinical trials. Properly designed factorial trials answer two or more suppressing virus permanently or at least for long periods [6] . The central barrier to this treatment success is HIV-1's rapid questions at the price of one conventional nonfactorial trial and provide insight into treatment interactions. An example is ISIS-evolution within a host and the resulting selection for drugresistant virus strains [7] . This dynamic nature of HIV-1 re-4, a randomized factorial trial that simultaneously assessed three treatments for patients with suspected myocardial in-quires that sequences of drug combinations are judiciously tailored to patients and that patients strongly adhere to the farction: early oral captopril, oral mononitrate, and intravenous magnesium sulphate [5] . We propose that the current climate demanding treatment regimen [8] .
In this treatment context, there are several ways in which knowledge of in vivo interactions would provide valuable guidance for treatment selection and administration. For one, it is similarly for showing that enhanced bioavailability of saqui-ual drug effects. To illustrate a rule, consider two antiretrovirals, A and B, and let absolute change in plasma HIV-1 RNA navir by ritonavir translates into an ritonavir/saquinavir positive clinical or virologic interaction. For patient management, a level from baseline to a prespecified follow-up time be the efficacy end point. Suppose the effect of A(B) is to drop virus physician's knowledge that two drugs work better in combination than expected from their efficacy as individual agents will load by d A (d B ) logs. One rule states that the treatments are additive (positively interact) if the A/B combination drops virus direct his or her emphasis on joint administration and adherence. Further, knowledge of in vivo negative interactions would load by an amount equal to (more than) d A / d B logs. A negative interaction occurs if A/B drops virus load by an help prevent administration of antagonistic combinations.
Understanding of the relationship between mutations in the amount less than d A / d B logs. A different addition rule would give a different interaction definition, so that the concept of HIV-1 genome and in vivo drug resistance and cross-resistance would also greatly assist tailoring of therapies. Since genetic drug interaction in people depends entirely on the expectation of how individual drug effects on the efficacy end point add. sequencing technology is advancing rapidly, there is a new opportunity to systematically collect this knowledge and apply See [11, pp 1058 -9] for further discussion on the inherent model-dependency of treatment interactions. it as a primary guide in patient management. As we elucidate, factorial and related designs are well suited for rapidly acquir-A drug interaction in one efficacy measure does not necessarily translate into a drug interaction in a different efficacy mea-ing this understanding, because the effect of several patterns of nucleotide or amino acid mutations on in vivo efficacy of sure. It depends on the model linking the two measures. To illustrate this, consider efficacy defined by the capability of multiple drug regimens can be investigated in a single study. Moreover, factorial designs permit assessment of interactions a protease inhibitor drug to render newly produced virions noninfectious. Define respectively h 0 and h* as the proportion between a mutation pattern class and a treatment class, which can potentially reveal extremely important insights for tailoring of newly produced virions that are noninfectious before and after drug administration, so that h Å (h* 0 h 0 )/(1 0 h 0 ) treatment assignments. For example, if a mutation in the protease amino acid residue M-46 (to I or L) and a mutation in measures the efficacy of the administered drug relative to a perfect drug. Since no available assay can directly measure the residue V-82 (to A, F, or T) significantly negatively interact with drug regimens A and B, in that A works well for those proportion of new virions rendered noninfectious, in order to estimate h, it is necessary to use a viral dynamics model linking with the M-46 mutation but poorly for those with the V-82 mutation, and vice versa for B, a very clear signal is sounded. this drug efficacy mechanism to an observable efficacy end point. , we describe elementary features of factorial and related structured designs and their model expresses the observable log change, d, in plasma HIV-1 RNA concentrations from baseline to a prespecified follow-use in combination antiretroviral trials. We argue for implementation of these designs, not only because they provide a up time, t, as a function of h, t, and the clearance rates of free virus (c) and productively infected T cells (d). systematic approach to evaluation of drug interactions and genotypic resistance, but also because they require substantially How does this viral dynamics model relate definitions of drug interaction on the two efficacy measures h and d? Consider fewer study subjects than conventional designs for comparisons of particular drugs or mutation patterns within a class. We sensible definitions of interaction in h and d. If drug A has efficacy h A Å 90%, and drug B has efficacy h B Å 50%, then a compare factorial and related designs to conventional designs, both by their theoretical properties and by application to com-natural definition of additivity is that combination A/B has drug efficacy h AB Å 95%. The general formula for additivity is that pleted and recently proposed combination antiretroviral trials. combination A/B has drug efficacy
Define a drug interaction in d as above. As we elaborate in the Drug Interactions in People
Appendix, under Wu et al.'s [13] viral dynamics model, these two definitions correspond only if the clearance rates, c and d, Drug interactions are typically studied in the laboratory, defined through concepts such as synergy. In people, an interac-and the plasma HIV-1 RNA measurement time, t, take particular values. Thus, a natural and clearly interpretable definition of tion is defined relative to a measure of tangible drug efficacy. For example, synergy in the laboratory may translate into syn-additivity for the observable efficacy end point, d, may correspond to an arbitrary definition of additivity for the unobservable ergy in the clinic [10] . Other measures are clinical (e.g., time to AIDS-defining illness or death), virologic (e.g., suppression efficacy parameter, h, and vice versa. This highlights the inherent model-dependency of relating interaction definitions on different of plasma HIV-1 RNA level), or immunologic (e.g., increase in CD4 cell count). For a given efficacy measure, interaction efficacy end points. More specifically, it suggests that viral dynamics models can be used to select a plasma HIV-1 RNA of two drugs is defined relative to a rule for addition of individ-with very good efficiency. For example, a treatment difference between the two NNRTIs is assessed by comparing the results from 200 subjects on NNRTI 1 with those from the 200 subjects on NNRTI 2 . Similarly, the main effect of PIs and NAs can be assessed with 200 subjects per drug level.
The capability of the factorial trial to simultaneously assess 3 main effects has considerable advantages over the conventional (PIs, NAs, and NNRTIs) are varied one at a time, with the remaining factors held fixed. Each individual trial provides an estimate of the effect of a single drug class at selected fixed measurement time so that an interaction in the observable meadrug levels of the other drug classes. For this estimate to have sure, d, reflects an interaction in the biologically meaningful broad clinical relevance, it is necessary to assume that the parameter h. treatment effect would be the same in combinations with other This paper aims to illustrate concepts rather than be exhausdrugs in the other drug classes -that, over the ranges of current tive, so henceforth we focus on the important case in which interest, the drugs act on the efficacy measure additively. Howthe primary end point is log drop, d, in plasma HIV-1 RNA ever, if the treatment effect is additive, the factorial design is concentrations and treatment effects add on the scale for d much more efficient, and if there is nonadditivity, the factorial defined above.
design, unlike the one-factor-at-a-time design, if adequately powered, can detect and estimate interactions that measure the nonadditivity [16] .
Factorial Designs
To illustrate the gain in efficiency, suppose there are 200 subjects in the 2 1 2 1 2 factorial design, 25 per arm. To In this section we define the factorial design, describe its elementary properties, and compare it to designs that have been obtain equal precision for the estimate of PI effect, the onefactor-at-a-time trial would need to have 200 subjects, 100 for extensively used in antiretroviral trials for HIV-1 infection. See jects would be required to study NAs and NNRTIs. Thus, to give estimates of the main effects of the three drug classes We have three main drug classes to investigate in combination: protease inhibitors (PIs), nucleoside analogues (NAs), and with the same precision as provided by the factorial design, the one-factor-at-a-time design would require 600 subjects -nonnucleoside reverse-transcriptase inhibitors (NNRTIs). These are factors in a factorial design. Particular drugs within a 3-fold increase. Another advantage of a factorial design is that one can test a drug class are levels of the factor. A trial with factorial design is one with simultaneous randomizations to the levels of each for and estimate the magnitude of interactions between drug classes. In this example, there are three possible interactions factor. This allows investigation of multiple scientific questions at no extra cost by decomposing the analysis of treatment between drug classes. For instance, consider PIs and NAs. The standard measure of the strength of interaction is the difference differences into main effects of each factor and interaction effects between factors. To illustrate, suppose we are interested between the average PI effect with the first NA and the average PI effect with the second NA. It is simple to detect interactions in two drugs in each drug class, labeled PI 1 , PI 2 , NA 1 , NA 2 , NNRTI 1 , and NNRTI 2 . A 2 1 2 1 2 factorial design is formed graphically as illustrated by figure 2 of Example 1. The existence of each interaction and each main effect can be tested by crossing all possible drug choices in the three drug classes (figure 1). Each subject is randomized to receive one of 8 triple for straightforwardly by an F test under standard assumptions [17] . A central advantage of testing for interactions and main combinations (i.e., simultaneously to one of the two drugs in each class). For instance, 400 subjects could be entered in effects is that it is possible to disentangle if superiority of a combination is due to main effects or positive drug interaction. random permuted blocks of 8, so that 50 individuals would receive each triple combination.
We now give an example of a completed nonfactorial trial conducted by the AIDS Clinical Trials Group (ACTG) in which An advantage of the factorial design is symmetry -each individual drug is given to half the subjects, and each double a factorial design would have been efficient and illuminating. (bDNA assay; Chiron, Emeryville, CA) from baseline to week in the 3-arm design three treatments can be compared pairwise, in the factorial design treatment differences can be assessed 24. If ACTG 229 had been designed as a 2 1 2 factorial trial, including a zidovudine monotherapy arm, it would have been between an additional 3 pairs of arms, but the sample size has only increased by a third. possible to assess the existence of an interaction between saquinavir and ddC. To mimic this, we constructed this arm by
To illustrate graphically various interactions, suppose that saquinavir and ddC interacted positively, so that the triple com-using plasma HIV-1 RNA data (bDNA assay; Chiron) from the zidovudine monotherapy arm of ACTG 116B/117 [19] .
bination zidovudine/saquinavir/ddC performed better than expected from the sum of the doubles zidovudine/saquinavir and Although this example lacks randomized control, it has partial validity in that the two studies have similar patient populations zidovudine/ddC. Then the lines would be nonparallel and diverging, as illustrated in figure 2 (bottom left). Figure 2 (bottom (at least 4 months of prior treatment with zidovudine and CD4 cell counts in the range 50 -300 copies/mL). To maximize their right) depicts a hypothetical negative interaction (antagonism), indicated by crossing lines, in which ddC has a negative effect comparability, subjects were sampled from ACTG 116B/117 according to the distribution of baseline CD4 cell count and with zidovudine and a positive effect with zidovudine/saquinavir. plasma HIV-1 RNA copy number for ACTG 229 subjects. Figure 2 (top) displays the mean treatment response for the We give a second example based on recently proposed trials to evaluate novel salvage regimens in people whose treatment 4 groups, with 76, 76, 73, and 73 subjects on the arms. The results are clear: triple therapy is superior to either double by PI fails. Example 2: protease failure salvage trial. Although the PI therapy (P Å .0052 vs. zidovudine/saquinavir, P Å .0042 vs., zidovudine/ddC), the double therapies perform similarly, and era has brought with it remarkable improvements over previously available antiretroviral therapies, a substantial propor-zidovudine monotherapy is worse than any combination (P Å .020 vs. zidovudine/saquinavir, P Å .019 vs. zidovudine/ddC, tion of PI-treated subjects do not maintain adequate viral suppression. For subjects with protease failure, it is imperative and P Å .0001 vs. zidovudine/saquinavir/ddC). The striking feature of the analysis is that the lines in figure 2 (top) are that alternative regimens be developed. A number of studies, including within the ACTG, have been initiated or are in devel-nearly perfectly parallel. This indicates the complete absence of an interaction, showing that, given a zidovudine background, opment to try to address this issue utilizing combination regimens that include approved and experimental dual PIs, saquinavir and ddC are additive (on the chosen scale) in their effect of suppressing virus load. One interpretation is that sa-NNRTIs, and the acyclic nucleoside phosphonate reverse-transcriptase inhibitor, adefovir. In this example, we discuss how quinavir and ddC work independently of one another without interference. This type of scientific insight was not possible factorial designs might be appropriately used for a ''salvage'' trial, which compares novel combination regimens. In con-with the original design. Another advantage is that, whereas structing treatment arms, we consider drugs proposed by groups factorial designs apply. We illustrate with the 2 1 2 1 2 factorial design discussed in Example 2. Some investigators within the ACTG. As in some current proposals, suppose all subjects receive the novel NA abacavir (also known as might be reluctant to add the fifth drug, adefovir, to a regimen containing ritonavir/saquinavir, in which case arms B and F 1592U89) and the novel NNRTI efavirenz (DMP-266). The experimental PI amprenavir (141W94) will be included in some are unacceptable. In this case, there are still two 2 1 2 factorial designs embedded within the remaining 6 arms, one comprising arms.
Two classes of therapy failures are considered: those given arms A, C, E, and G and the other comprising arms C, D, G, and H (figure 3, right). For each of these squares, 2 main effects indinavir and those given nelfinavir. For indinavir failures, consider the following two research questions: Which dual prote-and an interaction can be investigated. If another arm were unacceptable, for instance, arm D or H, then the trial would ase, ritonavir/saquinavir or amprenavir/nelfinavir, works best? Does adding adefovir to the regimen help? These questions are have 5 arms, of which 4 still compose a 2 1 2 factorial design.
The key point is that in selecting treatment arms for inclusion also of interest for nelfinavir failures, in which case the dual protease amprenavir/nelfinavir is replaced by amprenavir/indi-in combination antiretroviral trials, it is prudent to search for groups of arms that at least partially fit a factorial structure so navir. Separate 2 1 2 factorial trials could be conducted for indinavir failures and for nelfinavir failures, each with the capa-as much as possible can be learned at the cheapest price. We discuss sample size issues for these designs below (Sample bility to test which dual protease works the best and whether adefovir augments therapy, and to assess an adefovir/dual pro-Size Advantages of Factorial and Latin Square Designs). If one assumes there are no drug class interactions, then for tease interaction. Now consider indinavir and nelfinavir failures in the same many factorial designs, the mean treatment response of the combination arms in the empty cells can be imputed, with the study. Then amprenavir in combination with indinavir or nelfinavir can be taken as a PI level, and a single 2 1 2 factorial same precision as for the filled cells [20] . It is usually unadvisable to make this assumption, as it requires an excellent under-trial stratified by indinavir or nelfinavir failure could be conducted. Next, suppose a third randomization is of interest. For standing of joint in vivo drug dynamics. When the assumption is valid, however, it permits ascertainment of treatment effects instance, subjects could be randomized to an NNRTI, efavirenz or nevirapine, rather than all being assigned efavirenz. This of the unrepresented combinations. creates a 2 1 2 1 2 factorial design with factors NNRTI (efavirenz vs. nevirapine), dual PI (amprenavir/indinavir or nel- of resistance profiles and drug combination options, we need studies that facilitate systematic assessment of these correla-In practice, there are many sets of treatment combinations that can be arranged in a factorial configuration. However, tions for many mutation patterns and drugs. A mutation pattern is any representation of change in the HIV-1 genome that is because some of the combinations are not worth testing (e.g., zidovudine with stavudine, or ddI [dideoxyinosine] with ddC), of interest, such as a single-residue mutation (e.g., T-215-Y), a combination of mutations (perhaps in some temporal se-there will be some empty cells. In this situation, benefits can be reaped if the design contains factorial substructure. For quence), or any arbitrary delineation. We illustrate through examples how structured designs facil-instance, there may be an all-cells-filled factorial substructure within the full design for which the methods of analyzing itate systematic and efficient assessment of genotypic resis-/ 9d4c$$au48 06-15-98 13:24:16 jinfa UC: J Infect tance. In the analysis of 29 phenotypically indinavir-resistant HIV-1 isolates, Condra et al. [21] found that the relationship between protease mutations and resistance is complicated and difficult to fully elucidate. Mutations in at least 11 protease amino acid residues were associated with resistance, so apparently there are multiple resistance pathways. However, mutations at positions 46 or 82 were found in all indinavir-resistant Factorial designs might be useful for genotypic resistance trials. For example, we might conduct a salvage trial for indinavir and nelfinavir failures with the 4 treatment arms in the left or middle of figure 3. Consider a classification into two Instead of investigating two classes of mutation patterns and one class of treatments, two drug classes (say, NAs and PIs) and patterns of mutation: pattern I Å mutation at 82 but not at 46, and pattern II Å mutations at both 46 and 82. Enrolling subjects one class of mutation patterns could be investigated through a Latin square design. This kind of design permits assessment so that half have mutation pattern I and half have mutation pattern II would permit systematic genotypic resistance assess-of which NA works the best for each mutation pattern, which PI works the best for each mutation pattern, and which mutation ment without increasing the sample size or compromising the original objectives of the trial. With factorial designs, interac-pattern overall is most predictive of resistance. tions between mutation pattern classes and drug treatment classes can be investigated in the same way that interactions Sample Size Advantages of Factorial and Latin Square Designs between two drug classes are investigated. Results should be interpreted more cautiously though, because mutational pattern Generally, in the absence of an appreciable negative interaction, a factorial trial can detect meaningful main effect treat-is a classification factor rather than a randomization factor.
When more than one genetic classification factor is of inter-ment differences with small sample sizes. However, a factorial design with high power to detect main effects will have sub-est, the simple factorial design may not be practical. A trial with ''Latin square'' design (Latin square designs are com-stantially lower power to detect interactions (figure 5).
To illustrate these points concretely, consider the discussion monly used in pharmacokinetic and dosing clinical trials for many drugs, including antiretrovirals) could be conducted to in example 2 about the design of a salvage trial. Various trial designs could potentially be used that have between 5 and 8 test hypotheses about two classes of mutation patterns simultaneously and to compare salvage regimens. To illustrate, con-treatment arms and various degrees of factorial structure. We compare the powers of competing designs to detect a 0.5 log sider one class of three indinavir-resistance mutation patterns: mutation at 46 but not at 82, mutation at 82 but not at 46, and HIV-1 RNA change (treatment difference) in main and interaction effects. To illustrate an observed set of treatment responses mutations at both 46 and 82. Define another class of three mutation patterns: £3 protease mutations, 4 -6 protease muta-consistent with this difference, consider the 2 1 2 factorial design depicted in figure 3 (left), and suppose there is a mean tions, and §7 protease mutations. A 3 1 3 Latin square design with these two mutation pattern classes as rows and columns response of 2.0 log for both amprenavir-containing arms (each containing amprenavir/indinavir or amprenavir/nelfinavir) and and treatment regimens A, B, and C is depicted in figure 4 (left). Instead of randomly assigning three treatments to each 1.5 log for both ritonavir/saquinavir-containing arms. This specifies no interaction, so that the dual PI main treatment stratum (defined by row and column), only one treatment is assigned, hence the number of cells is reduced from 27 to 9. effect is the difference between the responses for the two amprenavir cells (each with amprenavir/indinavir or amprenavir/ The attraction of the design depicted in figure 4 is that it permits investigation of multiple scientific questions with the same nelfinavir) and the two ritonavir/saquinavir cells, equal to 0.5 log. If the mean response of the four treatment combinations number of subjects needed to investigate just one of these questions. First: Which treatment works best overall? Second and is 1.5 log for the upper-right cell and 1.0 log for the other three cells, then the alternative is a 0.5 log positive interaction. For third: Does the extent of resistance vary by mutation patterns in the rows, or in the columns? These three questions can be an-the power calculations, we assume the log HIV-1 RNA change is normally distributed, with the same SD (s) Å 0.7 (suggested swered through F tests of main effects under the assumption of no interactions between any of the three factors [17, pp 1091-by previous studies) in all arms. First, suppose the 8-arm 2 1 2 1 2 factorial trial depicted 6]. Fourth: For patients in each mutation classification (e.g., 46, 82), which treatment is the best? Fifth: How predictive of resis-in figure 3 (left and middle) was conducted, with 10 subjects per arm, a total of 80 subjects. Power to detect each of the tance is each combination of mutation patterns (e.g., £3, 82)? three drug class main effects (without interaction) is 81.6%. If a 2-arm trial in which the arms are the levels of A. Suppose the same number of subjects are evenly allocated in each three separate trials were run, we would require 80 patients in each study, a total of 240 patients, to have the same power to trial, and compare power to detect a main A treatment effect.
In the absence of an interaction, power may be mildly worse detect the main effects. If the sample size is increased to 40 per arm in a single factorial study of 320 patients, the power in the factorial than the 2-group design. This would occur solely because persons who receive a factor B treatment may to detect each of three drug class main effects is ú99.9%, while power to detect each of three interactions between drug have fewer events. Thus, to keep the power the same, the sample size should be raised by the ratio of the probability classes is 81.6%. Moreover, for each of the 6 embedded 2 1 2 factorial designs, there is 99.0% power to detect each of 2 of an event in a nonfactorial trial with one effective treatment to the probability of an event in a factorial trial in which both main effects and 57.5% to detect an interaction. Next, suppose that arms B and F are considered unacceptable, so that the treatments are effective [10, p 258]. For instance, consider example 1. Suppose the probability of failure on the zidovud-design is reduced to 6 arms with 2 embedded 2 1 2 factorial designs (figure 3, right). The total sample size has fallen from ine monotherapy arm is 50% and the effect of each combination zidovudine/saquinavir and zidovudine/ddC is to reduce 320 to 240 subjects, but due to the 2 missing cells, 4 rather than 12 main effects and 2 rather than 6 interactions can be this failure hazard by 30%. The sample size then would need to be increased by 13% [10, p 259]. This increase rises for investigated. For the investigatable effects, power is the same as given above, 99.0% or 57.5%. Finally, suppose arm H is lower probabilities of failure and for greater reductions of the hazard by the combination therapies. also unacceptable, so that now there are 200 subjects on 5 arms. Now 2 main effects and 1 interaction can be studied, Now suppose there is an interaction. If it is in the same direction as the main A effect, then the standard test (stratified with 99.0% or 57.5% power.
Sample-size comparisons between conventional designs log rank) for testing an A treatment effect is at least as powerful as this test in the 2-group trial [22] . On the other hand, power and factorial designs are qualitatively similar for binary, failure time, or other end points. There are, however, im-is less for the factorial trial if the interaction is negative. Of course, the same power to detect a main A effect in the factorial portant considerations unique to each end point. We briefly discuss the comparison for a failure time end point, such as trial is available to detect a main B effect. Thus, even in the case in which power is reduced, 2 questions can be addressed time to ''virologic rebound.'' For this end point, interaction is sensibly defined in terms of the drug efficacy measure at nearly the cost of 1. See [10, pp 258 -60] and [11, p 1060] for further discussion multiplicative reduction in the hazard of virologic failure. Consider a 2 1 2 factorial design, with factors A and B, and about the power of factorial designs for detecting main effects / 9d4c$$au48 06-15-98 13:24:16 jinfa UC: J Infect and interactions. We note that Latin square designs are opti-people that conventional designs cannot provide. The potential barrier to implementation of these designs is that the set of mally efficient for investigating main effects in that the fewest study subjects are needed to achieve high power [17] . treatment arms must fit a structure. The more rigid and complete the structure, the more efficient and informative the design. However, with the enormous number of new antiretroviral Discussion options, there now exist many sets of comparison arms of equally compelling interest that partially or wholly fit into the For many sets of antiretrovirals, factorial and Latin square designs allow for more rapid, precise, and insightful evaluation framework of factorial designs and are appropriate for these designs. Indeed, factorial antiretroviral trials are beginning to than do other approaches. These designs are also efficient for learning about genotypic resistance of patients in various fixed be implemented, as evidenced by ACTG 368, 388, and 384. The simple 2 1 2 factorial trial ACTG 368 addresses two mutation pattern classifications. This understanding may lead to identification of a simple rule, based on a genotype assay, questions: Should abacavir be added to a PI/NNRTI regimen? and Is twice-daily dosing viable, while the 3 1 2 factorial trial for tailoring therapy to patients. Ultimately, we need to develop rules for assigning sequences of drug combinations to patients ACTG 388 is designed to compare three combination regimens and to assess an adherence-intervention. A proposed design of with changing mutation profiles over time. To build these rules, ''adaptive'' trials are needed, in which trial participants with ACTG 384 specifies a 6-arm trial that fits the partial factorial structure of figure 3 (right) with A Å ddI/stavudine/nelfinavir certain new mutations emerging during the course of followup are randomized to a new regimen. In this paper, we have placebo/efavirenz, E Å zidovudine/lamivudine/nelfinavir placebo/efavirenz, C Å ddI/stavudine/nelfinavir/efavirenz, G Å not discussed use of efficient designs for adaptive trials, because drug-switching rules predictive of long-term virologic or zidovudine/lamivudine/nelfinavir/efavirenz, D Å ddI/stavudine/nelfinavir/efavirenz placebo, and H Å zidovudine/lamivud-clinical status have not yet been established. A staging of trials is called for -first nonadaptive trials can be used to identify ine/nelfinavir/efavirenz placebo. In this era of studying combination antiretroviral therapies, a fundamental component that sound switching rules, which can then be appropriately implemented in adaptive trials.
should be included in the process of selecting treatment regimens for clinical trials is conformity of the arms to factorial We discuss some criteria for judging the appropriateness of inclusion of treatments in factorial and Latin square trials. First, or partial factorial structure. The second conclusion is that factorial (and Latin square) for inferences about main effects to be interpretable, the investigators must believe that the results about any given treatment designs are tailor-made for efficiently and systematically studying genotypic correlates of drug resistance. These correlations factor can be combined over the levels of the other treatment factors. To illustrate this concept, in order for the factorial for two drug classes can be studied for the price of a conventional nonfactorial study of associations for one drug class. design of example 1 to be appropriate, it is required that the benefits of zidovudine/ddC over zidovudine are expected in Moreover, only with structured designs is it possible to make the important assessment of interactions between specific muta-those on saquinavir and saquinavir placebo, and the benefits of zidovudine/saquinavir over zidovudine are expected in those tion patterns and drug classes. on ddC and ddC placebo. Second, for the main effect estimates to have an unconfounded interpretation, it is necessary that
